RxDoctor Payments Data

Robert Dorman, MD

Internal Medicine · Arkadelphia, ARNPI 1598764896

Payments from drug & device makers

$644in general payments, 2019–2025

Across 33 payments — averaging $19.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$212
  • AbbVie$81
  • Boehringer Ingelheim$56
  • Sanofi-aventis U.S. LLC$54
  • E.r. Squibb & Sons, L.L.C.$53
  • Pfizer$38
  • plus $151 from 7 others

What the payments were for

  • Travel & lodging$21233%
  • Food & beverage$39261%
  • Education$406%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$644 in reported general payments places this provider in the 65th percentile of 614 internal medicine providers in Arkansas.

See all internal medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$216,355
Medicare patients
401
Services billed
4,099

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide176$206,687
OzempicSemaglutide175$172,279
JardianceEmpagliflozin117$103,874
EliquisApixaban70$62,576
JanuviaSitagliptin Phosphate67$43,282
FarxigaDapagliflozin Propanediol27$28,769
TrulicityDulaglutide20$26,783
EntrestoSacubitril/Valsartan14$19,118
XareltoRivaroxaban17$17,751
Emgality SyringeGalcanezumab-Gnlm13$17,188
JanumetSitagliptin Phos/Metformin Hcl18$14,498
InvokanaCanagliflozin22$13,447
Potassium Chloride214$11,007
Pantoprazole Sodium466$9,429
SavellaMilnacipran Hcl12$8,630

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$14$233,470196 claims
Novo NordiskOzempic, Levemir$28$174,993190 claims
Boehringer IngelheimJardiance$56$103,874117 claims
PfizerEliquis, Prempro$38$65,51683 claims
MerckJanuvia, Janumet, Belsomra$36$62,81197 claims
Johnson & JohnsonXarelto, Invokana$11$31,19939 claims
AstraZenecaFarxiga$22$28,76927 claims
AbbVieSavella, Linzess$81$15,24025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 614 internal medicine providers in Arkansas.

Other internal medicine in Arkadelphia

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →